IDEXX Laboratories, Inc. IDXX
At closeNov 4, 2026, 4:20 PM EST
After hours · Nov 4, 4:20 PM ET
- YTD
- +3.25%
- 1 year
- -3.26%
- Market cap
- 55.04B
- Revenue (ttm)
- 4.66B
- Profit margin
- 25.36%
- EPS (ttm)
- 14.84
- Shares out
- 78.79M
- P/E ratio
- 47.07
- Forward P/E
- 41.52
- YTD return
- +3.25%
- 1-year return
- -3.26%
- Volume
- 1.40M
- Avg volume
- 559.26K
- Open
- 686.23
- Previous close
- 672.04
- Day's range
- 681.70 – 713.74
- 52-week range
- 500.61 – 769.98
- Beta
- 1.54
- Analysts
- Buy
- Price target
- 708.83 (+1.5%)
- Earnings date
- Feb 1, 2027
2Y +282.57 (+67.93%)
Key statistics
- Enterprise value
- 53.72B
- PEG ratio
- 3.68
- Price / sales
- 11.80
- Price / book
- 29.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 9.90%
- Free cash flow
- 1.06B
- Total cash
- 197.54M
- Total debt
- 972.96M
- Return on equity
- 68.93%
- Short % of float
- 2.80%
- 50-day average
- 538.81
- 200-day average
- 572.20
Analyst view
Consensus: buy
- Target (low)
- 470.00
- Target (mean)
- 708.83
- Target (high)
- 810.00
- Strong buy4
- Buy5
- Hold4
- Sell1
- Strong sell0
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate 3.71.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Dec 30, 2026 | 3.36 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 3.73 | 3.96 | +0.23 | +6.17% |
| Aug 4, 2026 | Jun 30, 2026 | 3.94 | 4.27 | +0.33 | +8.38% |
| May 5, 2026 | Mar 31, 2026 | 3.41 | 3.47 | +0.06 | +1.76% |
| Feb 2, 2026 | Dec 31, 2025 | 2.93 | 3.08 | +0.15 | +5.12% |
| Nov 3, 2025 | Sep 30, 2025 | 3.14 | 3.40 | +0.26 | +8.28% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 3, 2026 | UBS | main | Neutral | Neutral |
| Oct 27, 2026 | UBS | main | Neutral | Neutral |
| Oct 16, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 12, 2026 | Keybanc | init | — | Sector Weight |
| Aug 11, 2026 | Barclays | main | Overweight | Overweight |
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- idexx.com
News
Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $810
UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $700
Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
IDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript
Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today
Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic
Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic
12 Health Care Stocks Moving In Monday's Intraday Session
IDEXX raises forecast, betting diagnostics can offset weak vet visits
Your note
Sign in to keep a note on IDXX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| EMERSON ANDREW | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 19, 2026 | 4,421 |
| ERICKSON MICHAEL G | Officer | Conversion of Exercise of derivative security | Feb 18, 2026 | 15,092 |
| FENNELL GEORGE | Officer | Conversion of Exercise of derivative security | May 31, 2026 | 10,433 |
| HUNT NIMRATA K | Officer | Sale | Mar 2, 2026 | 18,300 |
| KINGSLEY LAWRENCE D | Director | Sale | Sep 3, 2026 | 9,568 |
| LANE MICHAEL J | Officer | Conversion of Exercise of derivative security | Feb 12, 2026 | 8,615 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.37% | 8,170,178 | 5.71B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 5,152,213 | 3.60B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.95% | 3,896,521 | 2.72B | Jun 29, 2026 |
| State Street Corporation | 4.76% | 3,748,660 | 2.62B | Jun 29, 2026 |
| Invesco Ltd. | 4.58% | 3,611,416 | 2.52B | Jun 29, 2026 |
| Geode Capital Management, LLC | 3.25% | 2,562,886 | 1.79B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 2,504,327 | 1.75B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 2,043,087 | 1.43B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.17% | 1,709,209 | 1.19B | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 1,645,067 | 1.15B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 1,050,026 | 733.50M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 1,023,837 | 715.20M | Sep 29, 2026 |
